Lupin has launched Testosterone Topical Solution, 30 mg per actuation having received an approval from the United States Food and Drug Administration (USFDA) earlier. Testosterone Topical Solution, 30 mg per actuation had annual sales of around $179 million in the US (IQVIA MAT December 2017).
Lupin’s Testosterone Topical Solution, 30 mg per actuation is the generic equivalent of Eli Lilly and company’s Axiron Topical Solution, 30 mg per actuation. It is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
